EPA Endocannabinoid Epoxide Derivatives for Hydrolytic Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Endocannabinoid epoxides are less stable in the human body due to hydrolysis by soluble epoxide hydrolases and fatty acid amide hydrolase, reducing their biological activity and therapeutic potential.
Innovation Solution
Development of derivatives with improved stability at both epoxide and amide ends, synthesized to reduce hydrolytic susceptibility, retaining anti-inflammatory, anti-cancer, and anti-angiogenic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If endocannabinoid epoxides are used as therapeutic compounds, then anti-inflammatory and anti-cancer properties are achieved, but biological stability is reduced due to hydrolysis by sEH and FAAH
Solution Approach 1:
The patent extracts and modifies the vulnerable functional groups (epoxide and amide) of endocannabinoid epoxides to create derivatives with improved stability. Specifically, the epoxide group is replaced with aziridine or thiirane groups, and the amide group is modified with carbamate or ester groups, removing the sites that are susceptible to hydrolysis by sEH and FAAH.
Solution Approach 2:
The patent changes the chemical parameters of the endocannabinoid epoxide molecules by introducing different heteroatoms (nitrogen in aziridine, sulfur in thiirane) and modifying functional groups. These parameter changes result in compounds that resist hydrolysis by sEH and FAAH while maintaining biological activity.
2Duration of action of stationary object
If derivatives with improved stability are synthesized, then biological longevity is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent segments the endocannabinoid epoxide molecule into distinct functional regions and modifies them independently. The epoxide group is replaced with aziridine or thiirane, and the amide group is modified with carbamate or ester, allowing each segment to be optimized for stability while maintaining overall biological activity.
Solution Approach 2:
The patent creates composite molecular structures by combining the EPA backbone with modified functional groups (aziridine, thiirane, carbamate, ester). These composite derivatives exhibit enhanced stability and biological longevity while using established synthetic methodologies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stable derivatives exhibit enhanced biological longevity and therapeutic efficacy, offering potential as better candidates for therapeutics with fewer side effects and synergistic effects in disease conditions.
Implementation Method 1
soluble epoxide hydrolases (sEH) hydrolyze the epoxide to inactive diol compounds
Implementation Method 2
fatty acid amide hydrolase (FAAH) hydrolyzes the amide functional group to free acid
Data Source
AI summary
The present disclosure provides chemical compound derivatives of a class of biological lipid mediators known as endocannabinoids and methods of synthesizing the compositions. These compounds are useful for treating cancer, reducing inflammation, reducing platelet aggregation, and reducing angiogenesis.